Calidi Biotherapeutics Inc [AMEX: CLDI] gained 18038642% or 390169.72 points to close at $390170.0 with a heavy trading volume of 18038642 shares.
It opened the trading session at $0.3, the shares rose to $0.3248 and dropped to $0.268, the range by which the price of stock traded the whole day. The daily chart for CLDI points out that the company has recorded -83.53% loss over the past six months.
If we look at the average trading volume of 390.17K shares, CLDI reached to a volume of 18038642 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Calidi Biotherapeutics Inc [CLDI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLDI shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLDI stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Calidi Biotherapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 22, 2023. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on October 09, 2023, representing the official price target for Calidi Biotherapeutics Inc stock.
The Price to Book ratio for the last quarter was 1.31, with the Price to Cash per share for the same quarter was set at 0.34.
Trading performance analysis for CLDI stock
Calidi Biotherapeutics Inc [CLDI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -17.39. With this latest performance, CLDI shares dropped by -29.66% in over the last four-week period, additionally sinking by -83.53% over the last 6 months – not to mention a drop of -75.22% in the past year of trading.
Calidi Biotherapeutics Inc [CLDI]: A deeper dive into fundamental analysis
Return on Equity for this stock declined to -177.17%, with Return on Assets sitting at -177.17%.
Calidi Biotherapeutics Inc [CLDI]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLDI. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Calidi Biotherapeutics Inc go to 53.95%.
An analysis of Institutional ownership at Calidi Biotherapeutics Inc [CLDI]
There are presently around $17.24%, or 18.50%% of CLDI stock, in the hands of institutional investors. The top three institutional holders of CLDI stocks are: RED WAVE INVESTMENTS LLC with ownership of 0.62 million shares, which is approximately 1.1723%. CPR INVESTMENTS INC., holding 0.56 million shares of the stock with an approximate value of $$0.11 million in CLDI stocks shares; and CPR INVESTMENTS INC., currently with $$52694.0 in CLDI stock with ownership which is approximately 0.4945%.
